EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Meletios A Dimopoulos iD, Stephen Opat iD, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton iD, Björn E Wahlin iD, Ramon Garcia-Sanz iD, Helen McCarthy iD, Stephen Mulligan iD und 22 weitere

Journal of Clinical Oncology · 20.11.2023 · 41 (33) · 5099-5106

DOI: 10.1200/jco.22.02830 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2023. Verfasst von Meletios A Dimopoulos und 33 weiteren Autor:innen. Beteiligte Einrichtung: National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall survival were not reached. Any-grade adverse events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.9%), atrial fibrillation/flutter (23.5% v 7.9%), and pneumonia (18.4% v 5.0%) were more common with ibrutinib versus zanubrutinib; neutropenia (20.4% v 34.7%) was less common with ibrutinib versus zanubrutinib (cohort 1). Zanubrutinib was associated with lower risk of AE-related treatment discontinuation. Overall, these findings confirm the long-term response quality and tolerability associated with zanubrutinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaHumansPiperidinesPyrimidinesPyrazolesAdenine

Substanzen

PiperidinesPyrimidineszanubrutinibPyrazolesibrutinibAdenine

Autor:innen und Institutionen

  • National and Kapodistrian University of Athens, Athens, Greece.
  • Monash Health & Monash University, Clayton, VIC, Australia.
  • Centre for Waldenström's Macroglobulinemia & Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom.
  • Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland.
  • Flinders Medical Centre, Adelaide, SA, Australia.
  • Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia.

ORCID-Profile: Meletios A Dimopoulos, Stephen Opat, Paula Marlton, Björn E Wahlin, Ramon Garcia-Sanz, Helen McCarthy, Stephen Mulligan, Jorge J Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, Marina Motta, Tanya Siddiqi, Marek Trněný, Monique C Minnema, Christian Buske, Steven P Treon, Judith Trotman, Sheel Patel, Constantine S Tam

Zitieren

APA

Dimopoulos, M. A., Opat, S., D'Sa, S., Jurczak, W., Lee, H. P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Garcia-Sanz, R., McCarthy, H., Mulligan, S., Tedeschi, A., Castillo, J. J., Czyz, J., Fernández de Larrea, C., Belada, D., Libby, E., Matous, J., …, & Tam, C. S. (2023). Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. Journal of Clinical Oncology, 41(33), 5099-5106. https://doi.org/10.1200/jco.22.02830

Vancouver

Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, et al. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. Journal of Clinical Oncology. 2023;41(33):5099-5106. doi:10.1200/jco.22.02830

BibTeX
@article{Dimopoulos2023,
  author = {Dimopoulos, Meletios A and Opat, Stephen and D'Sa, Shirley and Jurczak, Wojciech and Lee, Hui-Peng and Cull, Gavin and Owen, Roger G and Marlton, Paula and Wahlin, Björn E and Garcia-Sanz, Ramon and McCarthy, Helen and Mulligan, Stephen and Tedeschi, Alessandra and Castillo, Jorge J and Czyz, Jaroslaw and Fernández de Larrea, Carlos and Belada, David and Libby, Edward and Matous, Jeffrey and Motta, Marina and Siddiqi, Tanya and Tani, Monica and Trněný, Marek and Minnema, Monique C and Buske, Christian and Leblond, Veronique and Treon, Steven P and Trotman, Judith and Chan, Wai Y and Schneider, Jingjing and Allewelt, Heather and Patel, Sheel and Cohen, Aileen and Tam, Constantine S},
  title = {Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {33},
  pages = {5099--5106},
  doi = {10.1200/jco.22.02830}
}
Kostenlos starten →